drugset / Trial / NCT02457208

PK Study of Anti-TB Drugs

NCT02457208

Phase 1 Completed 61 enrolled University of Oxford
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective descriptive and pharmacokinetic study will be conducted among newly diagnosed patients registered in the two SMRU TB clinics located on the Thai-Myanmar border. This study aims to recruit (1) 30 adults with HIV co-infection and (2) 30 adults without HIV co-infection in one year. Patients will be given the standard 6 month anti-TB drugs as per WHO guidelines.

Timeline

Start
2015-07-07
Primary completion
2018-01-14
Completion
2018-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Ethambutol Small molecule 275 mg
Subject Isoniazid Small molecule 150 mg
Subject Pyrazinamide Small molecule 400 mg
Subject Rifampin Small molecule 300 mg

Indications